Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.47−0.39 (-1.35%)
Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%
Pfizer net income
Net income is the profit left for shareholders after every expense, interest and tax.
Pfizer's net income for the twelve months ending Jun 28, 2026 was $4.33B, down 59.7% year over year. For fiscal 2025 it was $7.77B, down 3.2% from the year before. Over ten years it grew 1.1% a year on average. The highest annual figure on record is $31.37B in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.77B | -3.2% |
| FY2024 | Dec 31, 2024 | $8.03B | +279.0% |
| FY2023 | Dec 31, 2023 | $2.12B | -93.2% |
| FY2022 | Dec 31, 2022 | $31.37B | +42.7% |
| FY2021 | Dec 31, 2021 | $21.98B | +140.0% |
| FY2020 | Dec 31, 2020 | $9.16B | -42.8% |
| FY2019 | Dec 31, 2019 | $16.03B | +43.7% |
| FY2018 | Dec 31, 2018 | $11.15B | -47.7% |
| FY2017 | Dec 31, 2017 | $21.31B | +195.3% |
| FY2016 | Dec 31, 2016 | $7.22B | +3.7% |
| FY2015 | Dec 31, 2015 | $6.96B | -23.8% |
| FY2014 | Dec 31, 2014 | $9.14B | -58.5% |
| FY2013 | Dec 31, 2013 | $22.00B | +51.0% |
| FY2012 | Dec 31, 2012 | $14.57B | +45.6% |
| FY2011 | Dec 31, 2011 | $10.01B | +21.2% |
| FY2010 | Dec 31, 2010 | $8.26B | -4.4% |
| FY2009 | Dec 31, 2009 | $8.64B | +6.6% |
| FY2008 | Dec 31, 2008 | $8.10B | -0.5% |
| FY2007 | Dec 31, 2007 | $8.14B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 28, 2026 | -$248.00M | -108.5% |
| Q1 FY2026 | Mar 29, 2026 | $2.69B | -9.4% |
| Q4 FY2025 | Dec 31, 2025 | -$1.65B | -502.0% |
| Q3 FY2025 | Sep 28, 2025 | $3.54B | -20.7% |
| Q2 FY2025 | Jun 29, 2025 | $2.91B | +6997.6% |
| Q1 FY2025 | Mar 30, 2025 | $2.97B | -4.8% |
| Q4 FY2024 | Dec 31, 2024 | $410.00M | – |
| Q3 FY2024 | Sep 29, 2024 | $4.47B | – |
| Q2 FY2024 | Jun 30, 2024 | $41.00M | -98.2% |
| Q1 FY2024 | Mar 31, 2024 | $3.12B | -43.8% |
| Q4 FY2023 | Dec 31, 2023 | -$3.37B | -167.5% |
| Q3 FY2023 | Oct 1, 2023 | -$2.38B | -127.7% |
| Q2 FY2023 | Jul 2, 2023 | $2.33B | -76.5% |
| Q1 FY2023 | Apr 2, 2023 | $5.54B | -29.5% |
| Q4 FY2022 | Dec 31, 2022 | $4.99B | +47.2% |
| Q3 FY2022 | Oct 2, 2022 | $8.61B | +5.7% |
| Q2 FY2022 | Jul 3, 2022 | $9.91B | +78.1% |
| Q1 FY2022 | Apr 3, 2022 | $7.86B | +61.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.39B | +301.1% |
| Q3 FY2021 | Oct 3, 2021 | $8.15B | +454.5% |
| Q2 FY2021 | Jul 4, 2021 | $5.56B | +59.4% |
| Q1 FY2021 | Apr 4, 2021 | $4.88B | +45.4% |
| Q4 FY2020 | Dec 31, 2020 | $846.00M | – |
| Q3 FY2020 | Sep 27, 2020 | $1.47B | -80.9% |
| Q2 FY2020 | Jun 28, 2020 | $3.49B | -30.9% |
| Q1 FY2020 | Mar 29, 2020 | $3.36B | -13.6% |
| Q4 FY2019 | Dec 31, 2019 | -$583.00M | – |
| Q3 FY2019 | Sep 29, 2019 | $7.68B | +86.7% |
| Q2 FY2019 | Jun 30, 2019 | $5.05B | +30.3% |
| Q1 FY2019 | Mar 31, 2019 | $3.88B | +9.1% |
| Q4 FY2018 | Dec 31, 2018 | -$393.00M | -103.2% |
| Q3 FY2018 | Sep 30, 2018 | $4.11B | +44.9% |
| Q2 FY2018 | Jul 1, 2018 | $3.87B | +26.0% |
| Q1 FY2018 | Apr 1, 2018 | $3.56B | +14.1% |
| Q4 FY2017 | Dec 31, 2017 | $12.27B | +1483.7% |
| Q3 FY2017 | Oct 1, 2017 | $2.84B | +109.6% |
| Q2 FY2017 | Jul 2, 2017 | $3.07B | – |
| Q1 FY2017 | Apr 2, 2017 | $3.12B | – |
| Q4 FY2016 | Dec 31, 2016 | $775.00M | – |
| Q3 FY2016 | Oct 2, 2016 | $1.36B | – |
See a number that looks wrong?